Prevalence of the metabolic syndrome in an incident dialysis population

Hemodialysis International

Volumn 11, Issue 1, 2007, Pages 86-95

  Young, Daniel O ^a,b   Lund, Richard J ^a   Haynatzki, Gleb ^a   Dunlay, Robert W ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b Creighton Nephrology Associates   (United States)

Author keywords

ATP III; Cardiovascular disease morbidity and mortality; End stage kidney disease; Incident dialysis patients; Metabolic syndrome

Indexed keywords

ALBUMIN; GLUCOSE; HEMOGLOBIN;

ABDOMINAL OBESITY; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEGRO; PERITONEAL DIALYSIS; PREVALENCE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK FACTOR;

CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; ETHNIC GROUPS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 33846343251     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2007.00158.x     Document Type: Article

References (41)

1. U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2004.
2. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol. 2002; 13: 1918-1927.
3. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003; 63: 793-808.
4. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287: 356-359.
7. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003; 163: 427-436.
8. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004; 173: 309-314.
9. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107: 391-397.
10. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003; 108: 414-419.
11. Bonora E, Targher G, Formentini G, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004; 21: 52-58.
12. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U. S. adults. Ann Intern Med. 2004; 140: 167-174.
13. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant. 2004; 4: 1675-1683.
14. Holdaas H, Fellstrom B, Jardine A, Gimpelewicz C, Staffler B, Logan J. [SA-PO1048] prevalence and consequences of metabolic syndrome in a renal transplant population. In ASN Renal Week 2004, St Louis, MO, USA, 2004
15. Marchesini G, Forlani G, Cerrelli F, et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med. 2004; 21: 383-387.
16. Segura J, Campo C, Roldan C, et al. Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. J Am Soc Nephrol. 2004; 15(Suppl 1):S37-S42.
17. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003; 289: 2560-2572.
18. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: Clinical action thresholds. Am J Clin Nutrit. 2002; 76: 743-749.
19. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288: 2709-2716.
20. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004; 110: 1245-1250.
21. Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: The Casale Monferrato Study. Diabetes Care. 2004; 27: 2689-2694.
22. Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 1894-1900.
23. de Vries AP, Bakker SJ, van Son WJ, et al. Insulin resistance as putative cause of chronic renal transplant dysfunction. Am J Kidney Dis. 2003; 41: 859-867.
24. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant. 2004; 19: 2570-2575.
25. Reddan DN, Klassen PS, Szczech LA, et al. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant. 2003; 18: 1167-1173.
26. Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002; 287: 1548-1555.
27. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004; 15: 2959-2964.
28. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15: 539-553.
29. Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis. 2003; 41: 733-741.
30. Longenecker JC, Coresh J, Klag MJ, et al. Validation of comorbid conditions on the end-stage renal disease medical evidence report: The CHOICE study. Choices for healthy outcomes in caring for ESRD. J Am Soc Nephrol. 2000; 11: 520-529.
31. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989; 36: 286-290.
32. Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol. 2003; 14: 415-424.
33. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002; 13(Suppl 1):S28-S36.
34. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002; 17: 1684-1688.
35. Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutrit. 2004; 80: 324-332.
36. Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among "large" ESRD patients in the United States. Kidney Int. 2004; 65: 2398-2408.
37. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA. 2004; 291: 451-459.
38. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol. 2003; 14: S315-S320.
39. Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis. 2001; 38: 1351-1357.
40. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998; 31: 607-617.
41. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131-2138.